Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.52 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | PLK1 | P53350 | 1/20 | 0.49 |
| ▸ | ACACB | O00763 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4300221 | 0.85 | RAB9A (0.58) | MEN1KMT2ANPSR1HPGDTAS1R3 | |
| SCHEMBL6266664 | 0.83 | SYK (0.51) | MEN1KMT2AHPGDRAB9ANPC1 | |
| SCHEMBL6094225 | 0.83 | SYK (0.51) | MEN1KMT2AHPGDRAB9ANPC1 | |
| SCHEMBL10287161 | 0.81 | NPC1 (0.48) | MEN1KMT2ARAB9ANPC1EPHX2 | |
| SCHEMBL13825452 | 0.80 | MEN1 (0.51) | MEN1KMT2ARAB9ANPC1ACACB | |
| SCHEMBL13611517 | 0.79 | PLK1 (0.52) | MEN1KMT2ANPSR1HPGDTAS1R3 | |
| SCHEMBL13459410 | 0.79 | NPC1 (0.76) | NPSR1HPGDRAB9ANPC1PLK1 | |
| SCHEMBL12380408 | 0.78 | MEN1 (0.49) | MEN1KMT2ARAB9ANPC1ACACB | |
| SCHEMBL10294829 | 0.77 | NPSR1 (0.72) | MEN1KMT2ANPSR1HPGDTAS1R3 | |
| SCHEMBL13366141 | 0.77 | RAB9A (0.54) | MEN1KMT2ANPSR1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778305-B2 | PSMA-binding agents and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-07-15 | — | — | US | disclosed |
| US-20090286791-A1 | Amide Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286791-A1 | Amide Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286791-A1 | Amide Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286791-A1 | Amide Compounds | DLAT, DGAT2, DGAT1 | MEN1 4145/4885KMT2A 710/4885NPSR1 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.